Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 4Active not recruiting 4Recruiting 2Withdrawn 1Terminated 1Enrolling by invitation 1

Sponsor Class

OTHER 8INDUSTRY 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Patient Preference 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1

Interventions

pembrolizumab 185Carboplatin 133Paclitaxel 102Cisplatin 102Gemcitabine 86Pemetrexed 80durvalumab 75Nivolumab 66Docetaxel 56atezolizumab 52Bevacizumab 50Cyclophosphamide 49Dexamethasone 45Capecitabine 45Oxaliplatin 43130-nm albumin-bound paclitaxel 42Rituximab 40Fulvestrant 39Lenalidomide 38Fluorouracil 38Prednisone 32osimertinib 31olaparib 29Leucovorin 29venetoclax 28fludarabine 28Trastuzumab 27Doxorubicin 27Etoposide 25Cetuximab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × decitabine and cedazuridine drug combination × Clear all
NCT05403450 2026-02-23

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

Taiho Oncology, Inc.

Phase 1 Active not recruiting
33 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT05201066 2026-01-07

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Novartis

Phase 2 Active not recruiting
33 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
101 enrolled 1 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡